Advertisement
Advertisement
U.S. markets open in 7 hours 9 minutes
Advertisement
Advertisement
Advertisement
Advertisement

LexaGene Holdings Inc. (LXG.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4550-0.0050 (-1.09%)
At close: 02:00PM EST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4600
Open0.4500
Bid0.4250 x 0
Ask0.4700 x 0
Day's Range0.4500 - 0.4650
52 Week Range0.3600 - 1.5400
Volume69,087
Avg. Volume59,606
Market Cap54.2M
Beta (5Y Monthly)2.10
PE Ratio (TTM)N/A
EPS (TTM)-0.1200
Earnings DateJun 28, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for LXG.V

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      LexaGene Closes Multiple MiQLab Sales

      BEVERLY, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce two purchase orders from Kuma Veterinary Clinic and the Emergency Veterinary Services of Roanoke. Dr. Jack Regan, LexaGene’s Founder and CEO commented, “I’m pleased to announce that we have closed additional MiQLab System sales to private hospitals. Veterinarian

    • GlobeNewswire

      LexaGene Intends to Pursue Full Panel Pathogen Testing through the FDA

      BEVERLY, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced it intends to pursue both 510k clearance and CLIA-waiver from the FDA to utilize the full potential of the MiQLab System™ for syndromic testing at the point of care. Syndromic testing allows medical providers to simultaneously test patient spec

    • GlobeNewswire

      Leading Veterinary Academic, Dr. Jane Sykes, Joins LexaGene Board of Directors

      BEVERLY, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced Dr. Jane Sykes, BVSc(Hons), PhD, MBA, DipACVIM (Small Animal Internal Medicine) has joined the LexaGene Board of Directors. Dr. Sykes is the Executive Director of Innovation and Entrepreneurship, School of Veterinary Medicine at the University

    Advertisement
    Advertisement